All News

"I prefer doing transvaginal prolapse surgery with native tissue and always have. So I was not affected when mesh was restricted," says one urologist.

In this video, Gary Lemack, MD, offers a brief overview of overactive bladder treatments in development and explains their significance for providers and patients.

The benefits of holmium laser enucleation of the prostate with MOSES-enabled pulsed laser modulation justify its consideration as the gold standard surgical treatment for lower urinary tract symptoms related to benign prostatic hyperplasia, according to Amy E. Krambeck, MD.

Patients using anticholinergic medications for the management of overactive bladder (OAB) are at increased risk of new-onset dementia compared with individuals treated with the beta-3 agonist mirabegron (Myrbetriq), according to findings of a new population-based, retrospective study published online March 13, 2020, in BJU International.

Unhealthy eating, like that associated with the Western diet, is associated with notably worse semen quality and less favorable testicular function than healthier eating patterns, according to a study of nearly 3,000 young Danish men published in JAMA Network Open (2020; 3:e1921610).

The FDA has accepted for review Urovant Sciences’ New Drug Application for once-daily 75 mg vibegron for the treatment of patients with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.

A significant trend is occurring in the management of urethral stricture, with increased utilization of urethroplasty and decreased utilization of repeat endoscopic procedures, researchers at the University of Washington in Seattle report.

A study of kidney stone patients who were treated using ureteral access sheaths found no evidence of ureteral strictures an average of 4 years following ureteroscopy.

Results of a randomized controlled clinical trial provide a rationale for urologists to integrate behavioral treatments into their practice for managing men with lower urinary tract symptoms of overactive bladder, according to the study’s authors.

“If the long-term results prove to be as positive as the short-term results, then this could provide an intermediate option for patients with recurrent bulbar urethral strictures," says Sean P. Elliott, MD, MS.

A new tool for kidney stone ablation demonstrates strong potential to dust and fragment stones more quickly and efficiently than devices currently available in the United States. However, clinical studies must be performed before this technology can be used during lithotripsy nationally.

Two pharmaceuticals in late-stage development may offer new therapeutic options for patients with rare forms of hyperoxaluria.

“Although the raw number of augmentations and diversions have been relatively unchanged, the proportion of patients undergoing both surgeries declined while the proportion of patients undergoing Botox injections doubled over the past 5 years,” said Rita P. Jen, MD, MPH.

"This work is important to our field, because it represents an effort to personalize treatment approaches to particular patients’ needs," writes Brian R. Matlaga, MD, MPH.

Patients with kidney stones who rank their pain at the maximum level on a 100-point scale or whose number-one goal for treatment is to relieve pain are less likely to reach their treatment goals than other patients undergoing kidney stone treatment, a recent study found.

November 2019 proved to be a fruitful month for urology-specific FDA approvals, with the agency giving the green light to a new drug for complicated urinary tract infection, an implantable device for the treatment of overactive bladder/retention, and a digital product for strengthening of pelvic floor muscles and treatment of urinary incontinence in women.

It may be time to take a closer look at antibiotic prophylaxis prior to ureteral stent removal, according to new data reported at the AUA annual meeting in Chicago.

Selective bladder denervation, which targets the afferent nerves at the trigone only, appears to be an effective treatment for refractory overactive bladder patients, lasting up to 12 months regardless of whether the patient exhibits detrusor overactivity at baseline, according to a recent study from Canada.

The first long-term study of an implantable electrode for tibial stimulation to treat overactive bladder shows a sustained high responder rate and a clean safety profile, said Roger R. Dmochowski, MD, at the AUA annual meeting in Chicago.

Treatment for overactive bladder (OAB) improves OAB symptoms similarly in frail and nonfrail older patients with no difference in side effects, according to a multi-institutional study presented at the AUA annual meeting in Chicago.

A randomized trial found no difference between single-use polyvinylchloride (PVC) catheters and reused PVC catheters for patients with neurogenic bladder due to spina bifida.

"Patient perception is an important aspect of developing an effective treatment plan, and we should be able to arm patients with accurate data to help them make an informed decision," write Whitney Renee Smith, MD, and Gopal H. Badlani, MD.